Back

Oral fluoroquinolones and risk of aortic dissection and aortic aneurysm: a nationwide nested case-control study

27 August 2022 (12:15 - 13:00)
Organised by:
Congress Presentation Part of: Drug cardiotoxicity: what do we need to know? Cardiotoxicity of Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Jarl Emanuel Strange

Herlev and Gentofte Hospital, Copenhagen (Denmark)

6 More presentations in this session

Presentation thumbnail
Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Dose-dependency of diclofenac's cardiovascular risks: a series of nationwide emulated trials
Associate Professor M. Schmidt (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Cardiovascular risk following cannabinoid treatment for patients with chronic pain
Mrs N. Nouhravesh (Durham, US)
Abstract Slides
Presentation thumbnail
Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient
Mr E. Fort (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Drug cardiotoxicity: what do we need to know?

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET
You may be interested in
thumbnail
Webinar
Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer
thumbnail
Congress Session
Recent perspectives in cardio-oncology
thumbnail
Congress Session
Cardio-oncology: when therapy leads to failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources